Guardant Health announces RADIOHEAD study validates Guardant Reveal use

Guardant Health (GH) announced the first clinical readout from their collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy, published in Cancer Research Communications. The data found that the Guardant Reveal test successfully detected responses to immunotherapy across multiple solid tumor types in advanced-stage cancer patients. The study also showed Guardant Reveal identified non-responders up to five months earlier than standard methods, supporting the use of blood-based monitoring to predict treatment response.